Ono, Yukari et al. published their research in Bioorganic Chemistry in 2020 | CAS: 2213-63-0

2,3-Dichloroquinoxaline (cas: 2213-63-0) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. Quinoxaline and its analogues may also be formed by reduction of amino acids substituted 1,5-difluoro-2,4-dinitrobenzene (DFDNB),One study used 2-iodoxybenzoic acid (IBX) as a catalyst in the reaction of benzil with 1,2-diaminobenzene.Recommanded Product: 2213-63-0

Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein was written by Ono, Yukari;Ninomiya, Masayuki;Kaneko, Daiki;Sonawane, Amol D.;Udagawa, Taro;Tanaka, Kaori;Nishina, Atsuyoshi;Koketsu, Mamoru. And the article was included in Bioorganic Chemistry in 2020.Recommanded Product: 2213-63-0 This article mentions the following:

A series of quinoxaline-1,3,4-oxadiazole hybrids I [R = chloro, Ph, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, etc.; R1 = hydroxy, amino, 2-phenylethoxy, etc.] were synthesized and assessed for their anticancer potential on human leukemia HL-60 cells. Although these hybrids I exerted significant inhibition of HL-60 cell proliferation, they showed high cytotoxicity on human normal cells (WI-38). Utilizing information from mol. modeling of the hybrids I to the anti-apoptotic Bcl-2 protein, substructures including Ph, piperazine, piperidine and morpholine rings were added to their frameworks. The designed compounds I successfully induced apoptotic response on HL-60 cells with low toxicity on WI-38 cells. Furthermore, RT-PCR anal. demonstrated that these compounds I predominantly inhibited Bcl-2 expression. These findings highlight the great potential for the development of synthetic quinoxaline-1,3,4-oxadiazole hybrid derivatives as proapoptotic anticancer agents. In the experiment, the researchers used many compounds, for example, 2,3-Dichloroquinoxaline (cas: 2213-63-0Recommanded Product: 2213-63-0).

2,3-Dichloroquinoxaline (cas: 2213-63-0) belongs to quinoxaline derivatives. Condensed heterocycles of quinoxalines have become attractive targets in synthetic and medicinal chemistry due to their significant biological activities. Quinoxaline and its analogues may also be formed by reduction of amino acids substituted 1,5-difluoro-2,4-dinitrobenzene (DFDNB),One study used 2-iodoxybenzoic acid (IBX) as a catalyst in the reaction of benzil with 1,2-diaminobenzene.Recommanded Product: 2213-63-0

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider